Elisa Tribocco

Casale Monferrato, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: June 05, 2026

Patients with Irritable Bowel Syndrome Exhibit Aberrant Expression of Endogenous Retroviruses and SETDB1.

Patients with Irritable Bowel Syndrome Exhibit Aberrant Expression of Endogenous Retroviruses and SETDB1.

Journal: Cells

Published: December 03, 2024

Mycobacterium avium Subsp. paratuberculosis and Human Endogenous Retrovirus in Italian Patients With Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).

Mycobacterium avium Subsp. paratuberculosis and Human Endogenous Retrovirus in Italian Patients With Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).

Journal: Immunology

Published: September 13, 2024

Enhanced Transcription of Human Endogenous Retroviruses and TRIM28 Downregulation in Patients with Inflammatory Bowel Disease.

Enhanced Transcription of Human Endogenous Retroviruses and TRIM28 Downregulation in Patients with Inflammatory Bowel Disease.

Journal: Viruses

Published: August 20, 2024

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.

Journal: Journal of clinical medicine

Published: September 04, 2023

Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy.

Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy.

Journal: Journal of clinical medicine

Published: December 26, 2022

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease.

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease.

Journal: Frontiers in medicine

Published: December 05, 2022

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study.

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study.

Journal: Journal of clinical medicine

Published: July 01, 2021

Showing 1-8 of 8

Last Updated: 09/26/2026